Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus

Abstract

Rapid-acting insulin aspart was studied for efficacy and safety in seven patients with type 1 diabetes mellitus for more than 72 weeks. Pharmacokinetic profiles showed serum insulin levels peaking at 30 min, not the 90 min for regular insulin. Average HbA1c tended to decrease for 24 weeks, but did not change for 120 weeks thereafter. There were no statistically significant body weight changes over six months. The amounts of insulin and insulin aspart antibodies measured after 12 and 24 weeks of insulin aspart administration were not statistically significant. No adverse events were reported. All subjects appreciated the convenience of injection immediately before meals. Rapid-acting insulin aspart is safe and convenient for patients with type 1 diabetes. Through its use, they may improve their quality of life and get insulin levels to mimic those of non-diabetics.